Overcoming Resistance Mechanisms to Melanoma Immunotherapy
American Journal of Clinical Dermatology · 2025
DOI: 10.1007/s40257-024-00907-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Clinical Dermatology, 2025. Verfasst von David X Zheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Harvard Medical School,…. Hauptthemen laut MEDLINE: Melanoma, Drug Resistance, Neoplasm, Immune Checkpoint Inhibitors, Skin Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Institute on Aging.
Abstract (Originalsprache)
The advent of immune checkpoint inhibition has revolutionized treatment of advanced melanoma. While most patients derive survival benefit from established immunotherapies, notably monoclonal antibodies blocking cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1, a subset does not optimally respond due to the manifestation of innate or acquired resistance to these therapies. Combination regimens have proven efficacious relative to single-agent blockade, but also yield high-grade treatment toxicities that are often dose-limiting for patients. In this review, we discuss the significant strides made in the past half-decade toward expanding the melanoma immunotherapy treatment paradigm. These include newly approved therapies, adoption of neoadjuvant immunotherapy, and studies in the clinical trials pipeline targeting alternative immune checkpoints and key immunoregulatory molecules. We then review how developments in molecular and functional diagnostics have furthered our understanding of the tumor-intrinsic and -extrinsic mechanisms driving immunotherapy resistance, as well as highlight novel biomarkers for predicting treatment response. Throughout, we discuss potential approaches for targeting these resistance mechanisms in rational combination with established immunotherapies to improve outcomes for patients with melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. rjenkins@mgh.harvard.edu.
- Broad Institute of MIT and Harvard, Cambridge, MA, USA. rjenkins@mgh.harvard.edu.
Förderung
- NIA NIH HHS
- National Institute on Aging
Zitieren
APA
Zheng, D. X., Bozym, D. J., Tarantino, G., Sullivan, R. J., Liu, D., & Jenkins, R. W. (2025). Overcoming Resistance Mechanisms to Melanoma Immunotherapy. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-024-00907-7
Vancouver
Zheng DX, Bozym DJ, Tarantino G, Sullivan RJ, Liu D, Jenkins RW. Overcoming Resistance Mechanisms to Melanoma Immunotherapy. American Journal of Clinical Dermatology. 2025. doi:10.1007/s40257-024-00907-7
BibTeX
@article{Zheng2025,
author = {Zheng, David X and Bozym, David J and Tarantino, Giuseppe and Sullivan, Ryan J and Liu, David and Jenkins, Russell W},
title = {Overcoming Resistance Mechanisms to Melanoma Immunotherapy},
journal = {American Journal of Clinical Dermatology},
year = {2025},
doi = {10.1007/s40257-024-00907-7}
}
EUVIMED